INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Autor: INOVATYON study group, Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D'Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A.

Publikováno v: British Journal of Cancer, 128, 1503-1513
British Journal of Cancer, 128, 8, pp. 1503-1513

Background This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). Methods Patients with OC (up

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d614c2a7ed8f0a9a0d08a180564fbbf
http://hdl.handle.net/2066/291764

INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Autor: Colombo, N., Gadducci, A., Sehouli, J., Biagioli, E., Nyvang, G-B., Riniker, S., Montes, A., Ottevanger, N., Zeimet, A. G. G., Vergote, I. B., Funari, G., Baldoni, A., Tognon, G., De Censi, A., Churruca Galaz, C., Chekerov, R., Maenpaa, J., Rulli, E., Fossati, R., Poveda, A.

Publikováno v: Colombo, N, Gadducci, A, Sehouli, J, Biagioli, E, Nyvang, G-B, Riniker, S, Montes, A, Ottevanger, N, Zeimet, A G G, Vergote, I B, Funari, G, Baldoni, A, Tognon, G, De Censi, A, Churruca Galaz, C, Chekerov, R, Maenpaa, J, Rulli, E, Fossati, R & Poveda, A 2020, ' INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line ', Annals of Oncology, vol. 31, no. Suppl. 4, LBA30, pp. S1161 . https://doi.org/10.1016/j.annonc.2020.08.2260

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::03bf789d3834a246b705faabb822c34e
https://portal.findresearcher.sdu.dk/da/publications/b7581da9-200a-4387-b5b0-a2496ad4f023

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

Autor: Bookman, M. A., Okamoto, A., Stuart, G., Yanaihara, N., Aoki, D., Bacon, M., Fujiwara, K., González-Martín, A., Harter, P., Kim, J. W., Ledermann, J., Pujade-Lauraine, E., Quinn, M., Ochiai, K., Zeimet, A., Marth, C., du Bois, A., Hilpert, F., Pfisterer, J., Reuss, A., Friedlander, M., Wilson, M. K., Kridelka, F., Vergote, I., Berek, J., Dorig, Karam, A., Bekkers, R., Westermann, A., Gatsonis, C., Ng, C., Herráez, A. C., Ottevanger, N., Poveda, A., Redondo, A., Coleman, R., Lu, K., Gallardo-Rincón, D., Gomez-Garcia, E., Joly, F., Leary, A., Ray-Coquard, I., Burger, R., Moore, K. N., Fujiwara, H., Hasegawa, K., Gleeson, N., Levy, T., Rosengarten, O., Katsumata, N., Silverberg, S. G., Sugiyama, T., Chang, S. -J., Kim, B. -G., Nam, B. -H., Colombo, N., Ferrero, A, Lorusso, D., Scambia, G., Edmondson, R., Mcneish, I., Kohn, E., Hirte, H., Mcgee, J., Provencher, D., Sehouli, J., Wimberger, P., Maenpaa, J., Mirza, M. R., Oza, A., Welch, S., Gaffney, D., Small, W., Glasspool, R., Gourley, C., Millan, D., Zang, R., Zhu, J.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 28(suppl_8)

The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in acco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dbcad000c17fce8de6eb1a0b2c19346
https://pubmed.ncbi.nlm.nih.gov/29232472

Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era

Autor: Creutzberg, C.L., Kitchener, H.C., Birrer, M.J., Landoni, F., Lu, K.H., Powell, M., Aghajanian, C., Edmondson, R., Goodfellow, P.J., Quinn, M., Salvesen, H.B., Thomas, G, Ottevanger, N.

Publikováno v: International Journal of Gynecological Cancer, 23, 8, pp. 1528-34
International Journal of Gynecological Cancer, 23(8), 1528-1534
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
International Journal of Gynecological Cancer, 23, 1528-34

Item does not contain fulltext OBJECTIVE: The second Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting was held on December 1, 2012, and included international multidisciplinary representatives of the 24 member

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c9db24ef37b0c4233794931d71f1c67
https://hdl.handle.net/2066/125503